Comparable stake leader
Everest Medicines Ltd
SEC ownership of NovaBridge Biosciences
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001778016.
Disclosed value leader
CBC Investment I-Mab Ltd
Comparable rows
44/50
Latest evidence
08 Jul 2026
- Public ticker
- NBP on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Everest Medicines Ltd
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
44 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Everest Medicines Ltd
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
08 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001778016
- Issuer location
- Rockville, MD
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of NovaBridge Biosciences (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Everest Medicines Ltd
Disclosed value leader
CBC Investment I-Mab Ltd
Comparable rows
44/50
Latest evidence
08 Jul 2026
13D/G
13F
3/4/5
Lead comparable stake: 16%
6 rows are not safely comparable across share classes.
13D/G row: Everest Medicines Ltd
Showing 1-8 of 50 holder rows.
Quick read
Everest Medicines Ltd leads the comparable SEC ownership view at 16%.
44 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Everest Medicines Ltd's linked filing trail.
Comparable ownership
Top 5
Everest Medicines Ltd
16%
CBC Investment I-Mab Ltd
12%
MORGAN STANLEY
1.4%
AIHC Capital Management Ltd
1.1%
Siren, L.L.C.
0.76%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Everest Medicines Ltd |
13D/G
Everest Medicines Limited
|
16%
|
$90,577,645
42,524,716 shares
|
$0 | 05 Aug 2025 |
| CBC Investment I-Mab Ltd |
13D/G
Wei Fu
|
12%
|
$121,227,193
30,499,709 shares
|
+$11,952,376 | 29 Jan 2026 |
| MORGAN STANLEY |
13F
Company
|
1.4%
|
$7,123,795
3,653,228 shares
|
— | 30 Jun 2026 |
| AIHC Capital Management Ltd |
13F
Company
|
1.1%
|
$5,612,164
2,878,033 shares
|
— | 30 Jun 2026 |
| Siren, L.L.C. |
13F
Individual
|
0.76%
|
$3,909,241
2,004,739 shares
|
— | 30 Jun 2026 |
| MARSHALL WACE, LLP |
13F
Company
|
0.46%
|
$2,402,292
1,231,946 shares
|
— | 30 Jun 2026 |
| S.c.a. Candriam |
13F
Individual
|
0.43%
|
$2,206,373
1,132,563 shares
|
— | 30 Jun 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
Company
|
0.38%
|
$1,950,000
1,000,000 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$511,352.
Buys
$577,300
Insiders: 1
Sells
$65,948
Insiders: 3
Net
+$511,352
Shares: +192,128
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 230,000
Shares: 37,872
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 16,473 | $0 | $23,364 | -$23,364 |
| 3-6 | 230,000 | 21,399 | $577,300 | $42,584 | +$534,716 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to NovaBridge Biosciences. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
Mark Arnold Hagler
Net 12M change
+$511,352
Latest report
08 Jul 2026
Recent insider transactions for NovaBridge Biosciences
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Mark Arnold Hagler | NBP | 2025 Employee Share Option (right to buy) | Award | 949,050 | 949,050 | 08 Jul 2026 | Direct | |||
| Liwei Lorraine Lin | NBP | 2025 Employee Share Option (right to buy) | Award | 254,780 | 254,780 | 08 Jul 2026 | Direct | |||
| Srishti Gupta | NBP | 2025 Employee Share Option (right to buy) | Award | 3,000,000 | 3,000,000 | 06 Jul 2026 | Direct | |||
| Cong Claire Xu | NBP | Ordinary Shares | Sale | -1.48% | $3,992 | $0.8900 | -4,485 | 298,101 | 06 Jul 2026 | Direct |
| Cong Claire Xu | NBP | Ordinary Shares | Options Exercise | 4.28% | 12,432 | 302,586 | 04 Jul 2026 | Direct | ||
| Cong Claire Xu | NBP | Restricted Share Units | Options Exercise | -100% | -5,405 | 0 | 04 Jul 2026 | Direct | ||
| Fu Wei | NBP | Restricted Share Units | Award | 1,010,100 | 1,010,100 | 29 Jun 2026 | Direct | |||
| Fu Wei | NBP | 2025 Employee Share Option (right to buy) | Award | 2,900,580 | 1,087,720 | 29 Jun 2026 | Direct | |||
| Sean Wuxiong Cao | NBP | 2025 Employee Share Option (right to buy) | Award | 181,290 | 181,290 | 22 Jun 2026 | Direct | |||
| Sean Wuxiong Cao | NBP | Restricted Share Units | Award | 181,280 | 181,280 | 22 Jun 2026 | Direct | |||
| Phillip Andrew Dennis | NBP | Ordinary Shares | Sale | -5.1% | $5,606 | $0.6600 | -8,494 | 157,941 | 18 Jun 2026 | Direct |
| Phillip Andrew Dennis | NBP | Ordinary Shares | Options Exercise | 16.6% | 23,695 | 166,435 | 17 Jun 2026 | Direct | ||
| Phillip Andrew Dennis | NBP | Restricted Share Units | Options Exercise | -11.1% | -10,302 | 82,422 | 17 Jun 2026 | Direct | ||
| Cong Claire Xu | NBP | Ordinary Shares | Sale | -1.19% | $13,766 | $3.94 | -3,494 | 290,154 | 01 Jun 2026 | Direct |
| Cong Claire Xu | NBP | Ordinary Shares | Options Exercise | 3.3% | 9,382 | 293,648 | 30 May 2026 | Direct | ||
| Cong Claire Xu | NBP | Restricted Share Units | Options Exercise | -11.1% | -4,079 | 32,637 | 30 May 2026 | Direct | ||
| Sean Wuxiong Cao | NBP | Ordinary Shares | Sale | -37.9% | $42,584 | $1.99 | -21,399 | 35,073 | 14 May 2026 | Direct |
| Mark Arnold Hagler | NBP | Ordinary Shares | Purchase | $577,300 | $2.51 | 230,000 | 230,000 | 24 Apr 2026 | Direct |
* marks a reported price that did not pass the local price check.